Drug news
Menerba from BioNovo enters Phase III for menopause
BioNovo Inc.of Emeryville CA announced that it has received positive guidance from the FDA regarding the Company's Chemistry, Manufacturing and Controls plan for its lead drug candidate Menerba ,a novel selective estrogen receptor beta agonist. The FDA indicated its agreement with Bionovo's plan. This agreement provides the necessary groundwork for the Company to progress to pivotal Phase III clinical testing for treatment of vasomotor symptoms associated with menopause.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.